Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 combinations in metastatic PDAC
NCT02583477Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2016
- Primary completion
- Jul 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
A Phase 2 trial of durvalumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by AstraZeneca. Started Mar 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02583477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583477.